8-K filed February 20, 2025, 6:59 PM ET ticker TERN CIK 0001831363

leadership confidence high sentiment neutral materiality 0.40

Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns

Terns Pharmaceuticals, Inc.

Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.
Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.
Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.
Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.
Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts.

item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-024187
form_type: 8-K
ticker: TERN
cik: 0001831363
company_name: Terns Pharmaceuticals, Inc.
filed_at: 2025-02-20T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.146009+00:00
generated_at: 2026-05-26T09:25:09.126280+00:00
sec_items: ["5.02", "7.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-024187
json_url: https://secwatch.observer/filing/0000950170-25-024187.json
markdown_url: https://secwatch.observer/filing/0000950170-25-024187.md
text_url: https://secwatch.observer/filing/0000950170-25-024187.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/tern-20250220.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl Gordon

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-20
Filed: February 20, 2025, 6:59 PM ET

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Appointed

Robert Azelby

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-20
Filed: February 20, 2025, 6:59 PM ET

On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.

Source-grounded claims

7ea0624059

Carl Gordon resigned as Director at Terns Pharmaceuticals, Inc..

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

c96272df14

Robert Azelby was appointed as Director at Terns Pharmaceuticals, Inc..

On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

Carlyle appoints Kate Heinzelman as General Counsel; Jeff Ferguson to be Senior Advisor

Carlyle Group Inc. June 1, 2026, 8:00 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

Mr. Ferguson will become a Senior Advisor to Carlyle

Filing page SEC filing

HSY

Hershey names Mitchell Arends as Chief Supply Chain Officer; Jason Reiman to retire after 30 years

HERSHEY CO May 28, 2026, 4:26 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

Mr. Reiman will step down from his current role on June 22, 2026, and will remain with the Company as Senior Vice President, Supply Chain Modernization to assist with the transition of his responsibilities until his retirement.

Filing page SEC filing

FBIZ

Scott M. Ferris appointed to FBIZ Board, effective June 1, 2026

FIRST BUSINESS FINANCIAL SERVICES, INC. May 28, 2026, 4:02 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

appointed Mr. Scott M. Ferris as a Class III Director to fill the vacancy created by this increase.

Filing page SEC filing

WDC

Western Digital appoints Manuvir Das, former NVIDIA executive, to board

WESTERN DIGITAL CORP May 28, 2026, 9:08 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

On May 26, 2026, the Board of Directors (the “Board”) of Western Digital Corporation (the “Company”) unanimously appointed Manuvir Das to serve as a member of the Board

Filing page SEC filing

FVR

FrontView REIT appoints Welltower Co-President and CFO Tim McHugh to board as independent director

FrontView REIT, Inc. May 28, 2026, 7:05 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

On May 28, 2026, the board of directors (the “Board”) of FrontView REIT, Inc. (the “Company”) elected Tim McHugh to serve as a director of the Company, effective May 28, 2026.

Filing page SEC filing

TKNO

Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor

Alpha Teknova, Inc. June 1, 2026, 5:22 PM ET leadership Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

On May 27, 2026, Irene Davis, a member of the Board of Directors (the “Board”) of Alpha Teknova, Inc. (the “Company”) and a member of the Nominating and Corporate Governance Committee, notified the Company of her intention not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Meeting”) and to retire from the Board and all committees thereof, effective upon the date of the Meeting.

Filing page SEC filing

JOB

Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments

GEE Group Inc. June 1, 2026, 4:47 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.

Filing page SEC filing

SERA

Sera Prognostics director Jeff Elliott resigns ahead of annual meeting

SERA PROGNOSTICS, INC. June 1, 2026, 4:44 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.

Comparable filing

Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026

Filing page SEC filing

Source: SEC EDGAR

accession 0000950170-25-024187

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.